Murdoch University Neuroscientist Wins 2025 Aspire Award for MND Research
Dr. Yuval Gurfinkel, a neuroscientist at Murdoch University, has been awarded the prestigious 2025 Murdoch University Aspire Award by Business Events Perth. His groundbreaking research focuses on developing personalized genetic therapies for motor neuron disease (MND), a fatal neurodegenerative condition. This award recognizes his exceptional contributions to the field of neuroscience and his dedication to improving the lives of those affected by MND.
Dr. Gurfinkel's research aims to address the urgent need for innovative treatments for MND, a disease with no current cure. With approximately 2,000 Australians living with MND, the impact of his work is profound. The award also acknowledges the broader impact of his research, as MND disproportionately affects Western Australia, with a higher prevalence per capita compared to other Australian states.
The Aspire Award is a significant milestone for Dr. Gurfinkel, providing an opportunity to connect with other experts and further advance his research. He expressed his honor and gratitude, emphasizing the importance of collaboration in scientific progress. His work has already resulted in numerous co-authored publications, showcasing the potential of genetic therapy for MND.
Dr. Gurfinkel's research is conducted at the Personalized Medicine Centre at Murdoch University, where he collaborates with colleagues from the Perron Institute and King's College London. This interdisciplinary approach is crucial for developing effective treatments for complex diseases like MND.
The Aspire Awards, organized by Business Events Perth, celebrate the exceptional talent and leadership within Western Australia's academic and professional community. Dr. Gurfinkel's win highlights the potential for scientific breakthroughs to transform lives and society, aligning with Murdoch University's mission to drive positive change through research and education.
As part of his award, Dr. Gurfinkel will attend the 37th International Symposium on ALS/MND, where he will engage with industry leaders and collaborate on advancing MND therapies. His passion for collaborative research and dedication to improving patient outcomes are at the heart of his work, making him a deserving recipient of the 2025 Aspire Award.
